The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 ...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for ...

London: Janus Henderson Investors today announces the launch of the Janus Henderson Horizon Discovering New Alpha Fund (DNA), ...

We revealed that Richard Gurney is set to join Specialist Risk Group as head of specialty following his departure from Marsh, ...

MoonLake regains momentum after the FDA Type B meeting allows BLA submission for sonelokimab in HS without additional trials.

LG Display, the world's leading innovator of display technologies, will showcase a full lineup of strategic OLED products built on its world-leading ...

Q4 2025 Earnings Call Transcript January 8, 2026 TD SYNNEX Corporation beats earnings expectations. Reported EPS is $3.83, ...

Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / Janu ...

Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal ...